been impacted by altered patient flow. Until COVID-19, teledermatology was underutilized in the inpatient setting. FTF review remains the gold standard for inpatient consultations. Nonetheless, we conclude that most inpatient referrals can be confidently managed virtually, thereby increasing efficiency, reducing response time and obviating the need for FTF ward visits in a safe, timely and equitable manner. This is particularly significant in our current climate, reducing the attendant risk of cross-contamination between sites.

**Acknowledgements**

Ceri Llewellyn, Department of Medical Illustration, Aneurin Bevan Health Board, Newport, Wales

**Funding source**

None received.

**Conflict of interest**

None.

A. Lowe, F. M. Ali, N. M. Stone

1 Welsh Institute of Dermatology, University Hospital of Wales, Cardiff, UK, 2 Department of Dermatology, Royal Gwent Hospital, Newport, UK, 3 Department of Biosciences, Swansea University, Swansea, UK

*Correspondence: A. Lowe. E-mail: Ashima.Lowe@wales.nhs.uk

**References**

1 Gabel CK, Nguyen E, Karmouta R et al. Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease. J Am Acad Dermatol 2020. Epub ahead of print. https://doi.org/10.1016/j.jaad.2020.04.171

2 Dhaduk K, Miller D, Schiffman A et al. Implementing and optimizing inpatient access to dermatology consultations via telemedicine: an experimental study. Telederm E-HEALTH. 2021; 27(1):68–73. https://doi.org/10.1089/tmj.2019.0267.

3 Kroshinsky D, Cotliar J, Hughey LC, Shinkai K, Fox LP. Association of dermatology consultation with accuracy of cutaneous disorder diagnoses in hospitalized patients: a multicenter analysis. JAMA Dermatol 2016; 152 (4): 477–480.

4 Sharma P, Kovarik CL, Lipoff JB. Teledermatology as a means to improve access to inpatient dermatology care. J Telemed Telecare 2016; 22: 304–310.

5 Rismiller K, Cartron AM, Trinidad JCL. Inpatient teledermatology during the COVID-19 pandemic. J Dermatolog Treat 2020; 31: 441–443.

6 Lowe A, Pararajasingam A, Goodwin R. A UK-wide survey looking at teaching and trainee confidence in teledermatology: a vital gap in a COVID-19-induced era of rapid digital transformation? Clin Exp Dermatol 2020; 45: 876–879.

7 Lowe A, Pararajasingam A, Goodwin RG. A paradigm shift in trainee confidence in teledermatology and virtual working during the COVID-19 pandemic: results of a follow-up UK-wide survey. Clin Exp Dermatol 2021; 46: 544–547.

DOI: 10.1111/jdv.17257

---

**Good tolerance of hyaluronic acid injections during the period of the COVID-19 pandemic: observing a cohort of 1093 patients in a prospective, observational real-life study**

**Dear Editor,**

Dermatologists have questioned the possibility of continuing hyaluronic acid (HA) injections during the COVID-19 pandemic period, fearing especially an increase in immune complications. Therefore, the Group for Aesthetic and Corrective Dermatology of the French Society of Dermatology (gDEC) decided to set up a prospective, clinical study over the period May to July 2020 to follow a large patient cohort being injected with HA during the COVID-19 pandemic.

Overall, 14 dermatologists working in France, Belgium and Switzerland participated in the study. Each physician included all patients during the observation period that received facial HA injections. Participating physicians were encouraged to treat all patients according to their usual practice. Due to the COVID-19 pandemic, the hygiene measures were reinforced by the use of hydroalcoholic gel of physician and patient and the practitioners wearing a FFP2 masks at all times during the patient encounters.

All products injected were commercially available within Europe and were purchased by the physicians.

Two types of side-effects were recorded: (i) patient self-reported side-effects at any time of the study, (ii) side-effects discovered during the systematic follow-up by the treating physician at 1 and 3 months after the treatment.

A total of 1093 patients were included. Overall, 1927 syringes of HA were used, i.e. an average of 1.8 syringes per patient. 921 and 873 patients were reached, respectively, for the 1- and 3-month systematic follow-up. Ten patients with COVID-19 infection were injected later than 2 months after their infection. Five patients were diagnosed with an active COVID-19 infection within 3 months after their HA injection. 19 (1.7%) side-effects were reported, three self-reported and 16 (84% of side effect) observed at systematic follow-up. The recorded side-effects were those frequently associated with HA filler injections like erythema, oedema and temporary discomfort. They were all self-resolving within a few days and occurred in the absence of symptoms suggestive of COVID-19 infection. No further serious or unexpected side-effects were reported. A summary of the results can be found in Table 1.

Our study shows an excellent tolerance of HA injections during the COVID-19 pandemic. No immune complications, that
usually are triggered by viral or bacterial infections\textsuperscript{1,2} were reported. Most studies show that immediate and delayed immune HA complications are relatively quick to appear and are rare 2 months after the injection.\textsuperscript{3} A few case reports documented granuloma formation in patients injected with HA after receiving therapeutic cytokine (interferon) injections.\textsuperscript{4} In this context, it is feared that COVID-19 infections, known to cause sometimes a ‘cytokine storm’, lead to an increase in immune complications during the current COVID-19 pandemic. Data collected by André, Beleznay and Humphrey\textsuperscript{1,2,5} before the current sanitary crisis found a frequency of immune complications of 0.8\%, 0.5\% and 0.93\%, respectively. Other smaller studies\textsuperscript{3} reported comparable rates of immune complications. Based on these data, the expected number of patients with immune complications can be expected to be within five to 10 patients in our cohort; however, we did not find any immune complications. It is possible that due to the additional hygiene measures that physicians implemented in this study and the generally increased hygiene measures in the population at large, we may observe a reduction in viral and bacterial infectious disease and with this also a reduction in immune complications.

Our prospective study with a systematic follow-up at 1 and 3 months of over 1000 patients did not reveal any unexpected side-effects in the context of facial hyaluronic acid injections during the COVID-19 pandemic. Particularly, immune response-related complications were not observed in our entire study population.

Acknowledgements
None.

Conflict of interest
None.

M. Naouri\textsuperscript{1,2,*} S. Dahan\textsuperscript{3} A. Le Pillouer Prost\textsuperscript{4} P. Coutant-Foulc\textsuperscript{5} C. Raimbault\textsuperscript{5} F. Cucurella\textsuperscript{7} L. Beille\textsuperscript{8} M. Creusot\textsuperscript{9} M. Baspeyras\textsuperscript{10} M. Darchy\textsuperscript{11} R. Khalilouf\textsuperscript{12} H. Cartier\textsuperscript{13} I. Baratte\textsuperscript{14} M. Dubois\textsuperscript{15} O. Cogrel\textsuperscript{16} H. Laubach\textsuperscript{17,18} Group of Dermatology Esthétique and Correctrice de la Société Française de Dermatologie (GDEC)

\textsuperscript{1}Centre de Dermatologie, Esthétique et Laser de Nogent-sur-Marne, Nogent-sur-Marne, France, \textsuperscript{2}Centre Laser Universitaire, Service de Dermatologie, Hôpital St Louis, CHU AP–HP Nord – Université de Paris, Paris, France, \textsuperscript{3}Centre de Dermatologie, Esthétique et Laser de Toulouse, Toulouse, France, \textsuperscript{4}Centre de Dermatologie, Esthétique et Laser de Marseille, Marseille, France, \textsuperscript{5}Centre Dermatologique et Esthétique de la Femme, Nantes, France, \textsuperscript{6}Cabinet de Dermatologie, Esthétique et Laser de Metz, Metz, France, \textsuperscript{7}Cabinet de Dermatologie, Esthétique et Laser d’Aix, Aix les Milles, France, \textsuperscript{8}Cabinet de Dermatologie, Esthétique et Laser de Meylan, Meylan, France, \textsuperscript{9}Centre Dermatologique du Roy, Lasne – Plancanoit, Belgium, \textsuperscript{10}Cabinet de Dermatologie, Esthétique et Laser de Bordeaux, Cauderan, France, \textsuperscript{11}Centre de Dermatologie, Esthétique et Laser d’Orléans, Orléans, France, \textsuperscript{12}Centre de Dermatologie, Esthétique et Laser de Tours, Tours, France, \textsuperscript{13}Centre médical Saint Jean, Arras, France, \textsuperscript{14}Cabinet de Dermatologie, Esthétique et Laser de Champagne au Mont d’Or, Champagne au Mont d’Or, France, \textsuperscript{15}Cabinet de Dermatologie, Esthétique et Laser de Sanary sur Mer, Sanary sur Mer, France, \textsuperscript{16}Unité de Dermatologie Chirurgicale et Interventionnelle, Service de Dermatologie, CHU de Bordeaux, France, \textsuperscript{17}Centre Laser MD, Strasbourg, France, \textsuperscript{18}Consultation Laser, Service de Dermatologie, Hôpitaux Universitaires de Genève, Genève, Switzerland

*Correspondence: M. Naouri. E-mail: michaelnaouri@yahoo.fr

References
1 Andre P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA - Q-Med, Sweden) in European countries: a retrospective study from 1997 to 2001. \textit{J Eur Acad Dermatol Venereol}. 2004; 18: 422–425. https://doi.org/10.1111/j.1468-3083.2004.00934.x.
2 Beleznay K, Carruthers JD, Carruthers A, Mummet ME, Humphrey S. Delayed-onset nodules secondary to a smooth cohesive 20 mg/mL hyaluronic acid filler: cause and management. \textit{Dermatol Surg} 2015; 41: 929–939.
3 Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. \textit{J Eur Acad Dermatol Venereol} 2008; 22: 150–161.
4 Descamps V, Landry J, Francès C, Marinho E, Ratziu V, Chosidow O. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. \textit{Dermatology} 2008; 217: 81–84.
5 Humphrey S, Jones DH, Carruthers JD et al. Retrospective review of delayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients. \textit{J Am Acad Dermatol} 2020; 83: 86–95.

DOI: 10.1111/jdv.17271

Table 1 Tolerance of hyaluronic acid injections during the COVID-19 pandemic period

| Comparison of injection periods | Number of patients reached at 1 or 3 months | Number of patients reached at 3 months | Number of patients reached at 1 month |
|-------------------------------|---------------------------------|---------------------------------|-------------------------------|
| Number of patients injected  | 1093                            | 921                             | 873                           |
| Number of patients reached at 1 months | 921                             | 873                             | 5                             |
| Number of patients reached at 3 months | 873                             | 5                               | 873                           |
| Number of patients injected | 1927                            | 1927                           | 1927                          |
| Immediate self-reported side effect | 3                                | 3                               | 3                             |
| Discomfort + erythema + oedema | 3                                | 3                               | 3                             |
| Oedema only                   | 2                               | 2                               | 2                             |
| Immediate side effects on patients reached | 16                               | 16                              | 16                            |
| Discomfort + erythema + oedema | 16                               | 16                              | 16                            |
| Oedema only                   | 10                              | 10                              | 10                            |
| Ecchymosis                    | 2                               | 2                               | 2                             |
| Delayed self-reported side effects at 1 or 3 months | 0                                | 0                               | 0                             |
| Delayed side effects on patients reached at 1 or 3 months | 0                                | 0                               | 0                             |